Tags

Type your tag names separated by a space and hit enter

Prevalence of human papillomavirus genotypes in women with cervical cancer in Papua New Guinea.
Int J Gynaecol Obstet. 2012 Apr; 117(1):30-2.IJ

Abstract

OBJECTIVE

Prophylactic human papillomavirus (HPV) vaccines are currently not available in Papua New Guinea. Prior to introducing these vaccines, knowledge about the HPV genotypes present in cervical cancer in this region is necessary to determine whether the types covered by the 2 commercially licensed vaccines are the same as those in other regions of the world.

METHODS

Fresh, frozen cervical biopsies from 70 women with cervical cancer in Papua New Guinea were collected over a 3-year period from 2006-2009. HPV genotypes were detected using the Genera PapType assay.

RESULTS

Overall, 100% of the specimens were HPV DNA positive, with HPV types 16 and 18 being the most prevalent at 57.1% and 25.7% (95% CI, 0.45-0.68 and 0.17-0.37) respectively, followed by HPV 33 (10%; 95% CI, 0.05-0.19) and HPV 31 (4.3%; 95% CI, 0.01-0.12). Multiple genotypes were identified in 6 women (8.6%), with all biopsies containing HPV 16 and 1 other high-risk type.

CONCLUSION

The 2 most prevalent HPV types identified in women with cervical cancer in Papua New Guinea correspond to global data. This suggests that the currently available HPV vaccines could potentially reduce the burden of HPV-related cervical cancer in Papua New Guinea significantly.

Authors+Show Affiliations

Regional WHO HPV Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Melbourne, Australia. tania.tabone@mcri.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22325971

Citation

Tabone, Tania, et al. "Prevalence of Human Papillomavirus Genotypes in Women With Cervical Cancer in Papua New Guinea." International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, vol. 117, no. 1, 2012, pp. 30-2.
Tabone T, Garland SM, Mola G, et al. Prevalence of human papillomavirus genotypes in women with cervical cancer in Papua New Guinea. Int J Gynaecol Obstet. 2012;117(1):30-2.
Tabone, T., Garland, S. M., Mola, G., O'Connor, M., Danielewski, J., & Tabrizi, S. N. (2012). Prevalence of human papillomavirus genotypes in women with cervical cancer in Papua New Guinea. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 117(1), 30-2. https://doi.org/10.1016/j.ijgo.2011.11.022
Tabone T, et al. Prevalence of Human Papillomavirus Genotypes in Women With Cervical Cancer in Papua New Guinea. Int J Gynaecol Obstet. 2012;117(1):30-2. PubMed PMID: 22325971.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of human papillomavirus genotypes in women with cervical cancer in Papua New Guinea. AU - Tabone,Tania, AU - Garland,Suzanne M, AU - Mola,Glen, AU - O'Connor,Miriam, AU - Danielewski,Jennifer, AU - Tabrizi,Sepehr N, Y1 - 2012/02/10/ PY - 2011/09/02/received PY - 2011/11/07/revised PY - 2011/12/22/accepted PY - 2012/2/14/entrez PY - 2012/2/14/pubmed PY - 2012/7/24/medline SP - 30 EP - 2 JF - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics JO - Int J Gynaecol Obstet VL - 117 IS - 1 N2 - OBJECTIVE: Prophylactic human papillomavirus (HPV) vaccines are currently not available in Papua New Guinea. Prior to introducing these vaccines, knowledge about the HPV genotypes present in cervical cancer in this region is necessary to determine whether the types covered by the 2 commercially licensed vaccines are the same as those in other regions of the world. METHODS: Fresh, frozen cervical biopsies from 70 women with cervical cancer in Papua New Guinea were collected over a 3-year period from 2006-2009. HPV genotypes were detected using the Genera PapType assay. RESULTS: Overall, 100% of the specimens were HPV DNA positive, with HPV types 16 and 18 being the most prevalent at 57.1% and 25.7% (95% CI, 0.45-0.68 and 0.17-0.37) respectively, followed by HPV 33 (10%; 95% CI, 0.05-0.19) and HPV 31 (4.3%; 95% CI, 0.01-0.12). Multiple genotypes were identified in 6 women (8.6%), with all biopsies containing HPV 16 and 1 other high-risk type. CONCLUSION: The 2 most prevalent HPV types identified in women with cervical cancer in Papua New Guinea correspond to global data. This suggests that the currently available HPV vaccines could potentially reduce the burden of HPV-related cervical cancer in Papua New Guinea significantly. SN - 1879-3479 UR - https://www.unboundmedicine.com/medline/citation/22325971/Prevalence_of_human_papillomavirus_genotypes_in_women_with_cervical_cancer_in_Papua_New_Guinea_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0020-7292(11)00659-X DB - PRIME DP - Unbound Medicine ER -